Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory, High Risk Hematologic Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06208735
What this trial is testing

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Who this might be right for
B-Cell LeukemiaNon-Hodgkin's LymphomaB-cell Acute Lymphoblastic Leukemia+5 more
British Columbia Cancer Agency 24
Testing effectiveness (Phase 2)Study completedNCT01497496
What this trial is testing

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
H. Lee Moffitt Cancer Center and Research Institute 29
Testing effectiveness (Phase 2)Looking for participantsNCT04797767
What this trial is testing

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+10 more
University of Washington 62
Early research (Phase 1)Study completedNCT00003107
What this trial is testing

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+8 more
Indiana University
Early research (Phase 1)Ended earlyNCT00005787
What this trial is testing

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaNeutropenia
Northwestern University 3
Testing effectiveness (Phase 2)Looking for participantsNCT03418038
What this trial is testing

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Who this might be right for
Clonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic 80
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)Study completedNCT00004061
What this trial is testing

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Who this might be right for
LeukemiaLymphomaOral Complications
Memorial Sloan Kettering Cancer Center 111
Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Testing effectiveness (Phase 2)Study completedNCT02435849
What this trial is testing

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals 80
Testing effectiveness (Phase 2)Ended earlyNCT04730349
What this trial is testing

Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Who this might be right for
EpendymomaEwing SarcomaHigh-grade Glioma+7 more
Bristol-Myers Squibb 15
Testing effectiveness (Phase 2)Ended earlyNCT05086315
What this trial is testing

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia RefractoryMyelodysplastic Syndromes+1 more
Sanofi 101
Testing effectiveness (Phase 2)Study completedNCT02420912
What this trial is testing

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Who this might be right for
Loss of Chromosome 17pRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Ended earlyNCT03214666
What this trial is testing

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Who this might be right for
High-risk Myelodysplastic SyndromesAcute Myelogenous LeukemiaSystemic Mastocytosis+1 more
GT Biopharma, Inc. 12
Testing effectiveness (Phase 2)Study completedNCT04079296
What this trial is testing

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
Astellas Pharma Global Development, Inc. 43
Testing effectiveness (Phase 2)Study completedNCT00397579
What this trial is testing

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Who this might be right for
LeukemiaMyelodysplastic SyndromesBlastic Plasmacytoid Dendritic Cell Neoplasm
University of Texas Southwestern Medical Center 11
Testing effectiveness (Phase 2)Ended earlyNCT03594955
What this trial is testing

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Who this might be right for
Leukaemia
Sanofi 7
Not applicableStudy completedNCT02551718
What this trial is testing

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
University of Washington 34
Early research (Phase 1)Ended earlyNCT02319369
What this trial is testing

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Daiichi Sankyo 74
Next Page